Edwards Lifesciences Corporation (EW) Stock
EW Key Statistics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
CEO: Bernard J. Zovighian. Company website
EW — Frequently Asked Questions
What is the EW stock price today?
Edwards Lifesciences Corporation (EW) trades at $105.81, up 1.73% on the day, as of Nov 12, 2026 09:30 UTC.
What is Edwards Lifesciences Corporation's market cap?
Edwards Lifesciences Corporation has a market capitalisation of $60.99B, calculated from the live EW share price and shares outstanding.
What is the P/E ratio of EW?
EW trades at a trailing P/E of 59.89, from earnings per share of $1.77 over the last twelve months.
How much revenue does Edwards Lifesciences Corporation make?
Edwards Lifesciences Corporation generated revenue of $6.67B over the trailing twelve months, which puts the stock at 9.14 times sales.
What is the 52-week range for EW?
EW has traded between $74.66 and $106.05 over the past 52 weeks, and the last price is 0.2% below that high.
Is Edwards Lifesciences Corporation profitable?
Yes. Edwards Lifesciences Corporation keeps 15.30% of revenue as net income over the trailing twelve months.
What is the analyst price target for EW?
Wall Street analysts rate EW Buy, with an average price target of $108.70, 2.7% above the current price.
What sector is Edwards Lifesciences Corporation in?
Edwards Lifesciences Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Edwards Lifesciences Corporation?
Bernard J. Zovighian is the chief executive of Edwards Lifesciences Corporation, which employs 16,000 people.
Where can I track EW in real time?
QFI Terminal shows EW with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See EW live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open EW in Terminal See plans